SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $76

Morgan Stanley maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $79 to $76.

Benzinga · -

Morgan Stanley maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $79 to $76.